By Kelly Cloonan
Monogram Technologies has received clearance from the Food and Drug Administration for its mBôs Total Knee Arthroplasty system.
The company said Wednesday the clearance means it can start marketing the device, and is preparing for initial placements with surgeons in select areas of the U.S.
The placements aim to gather real-world clinical evidence and deepen surgeon engagement, the company said.
Monogram also gained regulatory approval from India's Central Drugs Standard Control Organization to import the system and initiate a 102-patient clinical investigation to evaluate its safety and effectiveness.
The company expects patient enrollment to begin shortly, with the first live surgeries in the next 90 business days.
The clearance and regulatory approval provide a clear path to commercial adoption in key markets, Chief Executive Ben Sexson said.
Shares rose 8.8% to $2.72 in after-hours trading Wednesday.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
May 14, 2025 17:17 ET (21:17 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.